GlassScriptPhysician profile
John J Lazarus
NPI 1336434729
$16,634.71
in general payments reported to CMS, 2019-2025
23 companies · $2,323 in 2025
The $2,323 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $914 · 2020: $725 · 2021: $377 · 2022: $786 · 2023: $11K · 2024: $746 · 2025: $2,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $11K · Food and Beverage: $3,145 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $10,642.57 |
| Food and Beverage | $3,144.74 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $10,511.32 | 2021-2025 | Resolute Onyx, Corevalve Evolut R, Micra |
| Boston Scientific Corporation | $2,696.12 | 2020-2025 | General - Vascular Access, Watchman Access System, Avvigo Guidance System |
| Medtronic Vascular, INC. | $825.82 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $576.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $398.40 | 2019-2023 | Farxiga, Brilinta |
| Janssen Pharmaceuticals, INC | $319.34 | 2019-2023 | Xarelto |
| Pfizer INC. | $315.87 | 2023-2025 | |
| Abiomed | $207.05 | 2019-2025 | Impella |
| Edwards Lifesciences Corporation | $129.87 | 2020 | |
| Amgen INC. | $105.04 | 2020-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.70 | 2019-2025 | Lifevest |
| Abbott Laboratories | $66.65 | 2020-2023 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $66.25 | 2019-2023 | Eliquis |
| Lilly USA, LLC | $62.42 | 2025 | Zepbound, Mounjaro |
| La Jolla Pharmaceutical Company | $58.47 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.75 | 2020-2024 | Jardiance |
| Cardiva Medical, INC. | $37.92 | 2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Esperion Therapeutics, INC. | $26.12 | 2021-2025 | Nexletol |
| Mannkind Corporation | $18.91 | 2025 | |
| Amarin Pharma, INC. | $18.10 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.04 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.19 | 2023 | |
| Cardiovascular Systems INC. | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lazarus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.